Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

Study Identifier
M16-948
CT.gov Identifier
NCT03413319
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Movement Disorders - Other
    • Study Drug
  • ABBV-8E12
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Subject completed Study C2N-8E12-WW-104 (NCT02494024) * Subject was not eligible to enroll in Study M15-562 (NCT02985879)
    Exclusion Criteria:
    * Subject weighs less than 35 kg at screening * Subject has any contraindication or inability to tolerate brain MRI * Subject has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results

    Protocol Summary

    The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

    Study Locations

    Location
    Status
    Location
    University of California, San /ID# 170113
    La Jolla, California, United States, 92093
    Status
    Not applicable
    Location
    Texas Health Physicians Group /ID# 170112
    Dallas, Texas, United States, 75218
    Status
    Not applicable